Posts by Amir T. Fathi, MD
-
Pursuing a Gentler Path to Treat—and Potentially Cure—Acute Myeloid Leukemia
The PARADIGM study compared intensive induction chemotherapy (IC) to a novel combination therapy, azacitidine and venetoclax (aza-ven), in patients newly diagnosed with acute myeloid leukemia and eligible for IC. Results showed that aza-ven clearly outperformed IC in patients enrolled on study.
-
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that enasidenib 100 mg/day was safe and well tolerated as maintenance therapy for IDH2-mutated myeloid malignancies after hematopoietic cell transplantation and showed preliminary clinical activity.
-
Ivosidenib Shows Promise As Maintenance Therapy for AML After Bone Marrow Transplant
Amir T. Fathi, MD, Yi-Bin Chen, MD, Zachariah DeFilipp, MD, Areej El-Jawahri, MD and colleagues found in a phase 1 trial that ivosidenib was safe and well tolerated as maintenance therapy for acute myeloid leukemia following allogeneic hematopoietic cell transplantation, and two-year outcomes were promising.
Biography
Amir T. Fathi, MD, is program director of the Center for Leukemia in the Mass General Brigham Cancer Institute and an associate professor of Medicine at Harvard Medical School.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.